Company / Free Cash Flow
GeneDx Holdings Corp. Free Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$14.3M
FY2025
5-year range
-$326.3M / $14.3M
FY2021-FY2025
Trend
+142.0%
vs FY2024
Sector context
#107 of 145
Health Care
What the data says
At $14M, GeneDx Holdings Corp.'s free cash flow ranks #107 of 145 in the Health Care sector. Free Cash Flow has increased for 3 consecutive years, from -$326M in FY2022 to $14M in FY2025.
Based on SEC 10-K filings.
$14M in FY2025.
Improved from -$185M to $14M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 145 in Health CareTop 74% of 145This company $14.3M Sector average $770.9M
▼
-98.1% below sector average
Key checks
Key Insights
- GeneDx Holdings Corp.'s free cash flow has grown for 3 consecutive years.
- In FY2025, free cash flow increased 142.0% year-over-year.
- Ranks #107 out of 145 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.3M | +142.0% |
| FY2024 | -$34.0M | +81.7% |
| FY2023 | -$185.4M | +43.2% |
| FY2022 | -$326.3M | -63.3% |
| FY2021 | -$199.8M | -70.5% |
| FY2020 | -$117.2M | -282.4% |
| FY2019 | -$30.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026